

1 **Hybrid immunity from SARS-CoV-2 delta variant surge induced low to**
2 **undetectable levels of neutralizing antibodies against Omicron variant**

3
4 Janmejay Singh^{1*} Heena Shaman^{1*}, Balwant Singh^{1*}, Anbalagan Anantharaj¹, Kamal
5 Pargai¹, Partha Chattopadhyay^{3,4}, Priti Devi^{3,4}, Ranjeet Maurya^{3,4}, Pallavi Mishra³,
6 Namrata Kahlon², Rajesh Pandey³, Anil Kumar Pandey² and Guruprasad R.
7 Medigeshi^{1#}

8 1: Bioassay Laboratory, Translational Health Science and Technology Institute,
9 Faridabad, Haryana. INDIA.

10 2: Employees State Insurance Corporation Medical College and Hospital, Faridabad,
11 Haryana, INDIA.

12 3: INtegrative GENomics of HOst-PathogEn (INGEN-HOPE) laboratory, CSIR-Institute
13 of Genomics and Integrative Biology, Delhi, INDIA.

14 4: Academy of Scientific and Innovative Research (AcSIR), Ghaziabad-201002, India.

15

16 *** These authors contributed equally**

17

18 **# Corresponding author:**

19 Guruprasad R. Medigeshi, PhD

20 Translational Health Science and Technology Institute,

21 P.O. Box # 4, Faridabad-Gurgaon Highway,

22 Faridabad 121001. INDIA.

23 Tel: +91-0129-2876311. Email: gmedigeshi@thsti.res.in

24

25 **ABSTRACT**

26 SARS-CoV-2 variants are emerging at frequent intervals with an ability to transmit faster
27 and evade the immune responses. Most of Indian adults have received one or two
28 doses of vaccination and, have also been infected naturally during the first and second
29 waves. However, whether or not this hybrid immunity is protective against the emerging
30 variants has not been determined. We found that a single dose of ChAdOx1 nCoV-19
31 vaccine in individuals with prior history of COVID-19 infection induced high levels of
32 neutralizing antibodies which associated with protection from infection. Natural infection
33 during the delta variant surge generated neutralizing antibodies against other lineages
34 including the omicron variant. However, most of the subjects had undetectable levels of
35 antibodies to neutralize omicron variant in the follow-up samples collected after six
36 months suggesting that a large majority of people in India are at risk of infection by
37 omicron variant due to waning antibody titers.

38

39 **Keywords:** COVID-19; RBD; Neutralizing antibodies; FRNT; ELISA; Omicron; Delta

40

41 **INTRODUCTION**

42 Most adults in India have received at least one dose of vaccination and have also been
43 infected naturally during the first and second waves of SARS-CoV-2 pandemic.
44 However, there are no reports on the effect of prior humoral immunity from natural
45 infection on vaccine-induced antibody responses in India. In addition, there is no data
46 on the longevity of such antibodies. We tested whether this hybrid immunity
47 (infection+vaccination) is protective against the SARS-CoV-2 variants of concern (VoC).
48 We assessed the neutralization titers of antibodies prior to and after natural infection
49 with delta variant in a cohort of subjects who had received a single dose of ChAdOx1
50 nCoV-19 vaccination. We found that prior history of COVID-19 infection led to boosting
51 of antibody responses and protected all the vaccinated subjects from infection by delta
52 variant indicating a strong correlation between neutralizing antibody titers and protection
53 from infection or severe disease. A subset of these patients also had neutralizing
54 antibodies to the Omicron (B.1.1.529) variant. However, the neutralizing antibody titers
55 reduced by half against the ancestral and delta variants and were below the level of
56 detection of the assay for Omicron variant after six months.

57

58 **MATERIALS AND METHODS**

59 **Human Ethics**

60 The study was approved by the Institutional ethics committees for human research at
61 ESIC Hospital and Medical College (No.134/R/10/IEC/22/2021/02) and THSTI (THS
62 1.8.1/ (93)). Informed consent was obtained from all the participants.

63

64 **Human Samples**

65 *ChAdOx1 nCoV-19 cohort*: Subjects (age 25-46) visiting ESIC Medical College &
66 Hospital, Faridabad for vaccination were enrolled into the study after obtaining written
67 informed consent. About 4 ml of whole blood was collected for serum preparation four
68 weeks after first dose of vaccination. Nasopharyngeal/Oropharyngeal (NP/OP) swabs
69 were collected from patients with symptoms of COVID-19 infection. Total RNA was
70 isolated to detect SARS-CoV-2 using COVIDsure multiplex real time RT-PCR kit
71 (Trivitron Healthcare) either at Employees State Insurance Corporation (ESIC) Medical
72 College & Hospital or at the bioassay laboratory Translational Health Science and
73 Technology Institute, Faridabad. Clinical presentations were mild to moderate fever, dry
74 cough, and loss of sense of smell and taste. All COVID-19 positive patients were self-
75 isolated and recovered without any need for clinical intervention or hospitalization. A
76 follow-up blood sample was collected after 3-4 weeks post-recovery and after six
77 months.

78

79 **Whole genome sequencing**

80 Three of the COVID-19 RNA samples were sent for whole genome sequencing as
81 described in supplementary information and the genome sequences were deposited on
82 the National centre for biotechnology database (MZ356901; MZ356904; MZ646055).

83

84 **Quantitative RBD ELISA**

85 Recombinant spike protein receptor binding domain (RBD) ELISA was performed as
86 described earlier [1, 2]. Detailed description is provided in the supplementary
87 information.

88

89 **Virus microneutralization assay**

90 Virus microneutralization assay by focus reduction neutralization titer assay using
91 indicating virus isolates was performed as described earlier [2].

92

93 **Statistical analysis**

94 Data was analysed and final graphs were prepared using GraphPad Prism (Version 9)
95 software. Statistical significance was estimated by two way ANOVA or Mann-Whitney
96 test with correction for multiple comparisons by Bonferroni-Dunn method.

97

98 **RESULTS AND DISCUSSION**

99 **A single dose of vaccination boosts antibody levels in seropositive individuals**

100 Less than 10 % of the Indian population had received one dose of COVID-19 vaccine at
101 the onset of second wave of COVID-19 in April 2021 and recent reports including
102 results from our group attribute this sudden spike in cases to the capacity of the virus to
103 escape neutralization by antibodies thereby compromising vaccine effectiveness and
104 increased infectivity and transmission of Delta variant [3-7]. To further understand how
105 vaccination and neutralizing antibodies impact Delta variant and disease outcomes, we
106 enrolled 25 subjects (Median age 31; 9 Female, 16 Male) out of which 20 subjects
107 received their first dose of ChAdOx1 nCoV-19 vaccine and 18 of the 20 subjects

108 consented for collection of blood samples three weeks after the first dose of vaccination
109 to quantitate serum antibodies against the receptor-binding domain (RBD) of SARS-
110 CoV-2 spike protein by quantitative ELISA. 5 subjects were non-vaccinated controls. 8
111 of the 20 vaccinated subjects were seropositive at least three months prior to receiving
112 the first dose of vaccine. Geometric Mean Titers (GMT) of antibodies against the RBD
113 of SARS-CoV-2 spike protein in subjects with no prior history of COVID-19 infection was
114 58.9 ELU/ml (95% CI: 25.3 - 137.3) as compared to 562.5 ELU/ml (95% CI: 123.9 -
115 2555) in subjects who had prior history of COVID-19 clearly demonstrating a ten-fold
116 higher levels of antibodies after one dose of vaccination (Fig. 1A). The GMT of
117 antibodies in non-vaccinated subjects was 8.6 ELU/ml (95% CI: 2 - 36.7) which was
118 below the limit of quantitation (12 ELU/ml) of the assay. As the second wave of COVID-
119 19 coincided with the study, 8 of the 25 subjects showed symptoms of COVID-19 and
120 were diagnosed positive by RT-PCR. Interestingly, all the eight subjects had no history
121 of COVID-19 infection before the second wave and six of the eight subjects had
122 received the first dose of ChAdOx1 nCoV-19 vaccine. The GMT of RBD antibodies prior
123 to second wave infection in subjects who tested COVID-19 positive was 22.5 ELU/ml
124 (95% CI: 7.7 - 65.6) whereas the same was 194.4 ELU/ml (95% CI: 66.0 - 572.2) in
125 subjects who remained uninfected or did not show any symptoms of infection (Fig. 1B).
126 All the eight subjects who were infected showed mild to moderate symptoms and
127 recovered after home isolation. These results show a strong association between high
128 levels of pre-existing RBD antibody titers and protection from infection or from severe
129 disease. This also suggests that natural infection before the second wave of COVID-19
130 (in India) or even one dose of vaccine conferred protection from reinfection or severe

131 disease in this age group. We performed paired analysis for GMT of RBD antibodies
132 prior to and after second wave infection. Mean titers of antibodies in individuals who
133 were COVID-19 positive in the second wave increased from 22.5 ELU/ml (95% CI: 7.7 -
134 65.6) to 629.5 ELU/ml (95% CI: 219.5 - 1805) (Fig. 1C). We did not observe any
135 significant change in antibody levels in individuals who were not infected during the
136 second wave. The antibody levels in these subjects was 135.4 ELU/ml (95% CI: 46.2 -
137 396.9) which showed a declining trend with a titer of 80 ELU/ml (95% CI: 29.6 - 216.8)
138 in the second bleed further demonstrating lack of exposure to SARS-CoV-2 in these
139 subjects (Fig. 1D).

140

141 The second wave of COVID-19 infection between March-May 2021 in India was mostly
142 due to B.1.617.1 and B.1.617.2 variants[8]. We sequenced viral RNA from three of the
143 positive samples in our study and found them to be either B.1.617.1 or B.1.617.2. To
144 verify the neutralization potential of antibodies in the serum samples of subjects from
145 this study, we estimated 50% virus neutralization titers from pre- and post-infection
146 serum using a focus reduction microneutralization assay (FRNT₅₀) against the B.6,
147 B.1.1.7 and B.1.617.2 lineages respectively [2, 6]. We first analyzed the effect of single
148 dose vaccination with ChAdOx1 nCoV-19 in subjects who had the history of prior
149 COVID-19 infection. Samples collected three weeks after first dose of vaccination
150 showed that the GMT for virus neutralization were higher by over one order of
151 magnitude in individuals with prior history of COVID-19 infection as compared to those
152 with no prior history of COVID-19 infection (Table 1) suggesting that a single dose of
153 vaccination boosts the antibody titers due to T and B-cell memory responses. In order to

154 further verify if the pre-infection antibody titers correlate with protection from infection or
155 severe disease, the data was analyzed based on the infection status in the second
156 wave of COVID-19 which followed few days after the collection of first bleed. The pre-
157 infection GMT for virus neutralization of subjects who got infected in the second wave
158 (n=8) was 71 (95% CI: 42, 118), 44 (95% CI: 25, 78) and 34 (95% CI: 34, 46) for B.6,
159 Alpha and Delta variants respectively (Fig. 2A-C) (Supplementary Table S1). The GMT
160 of neutralizing antibodies in the first bleed after one dose of vaccination in subjects who
161 were seronegative prior to vaccination and were protected from SARS-CoV-2 infection
162 during the second wave was 185 (95% CI: 129, 265), 67 (95% CI: 46, 99) and 83 (95%
163 CI: 40, 174) for B.6, Alpha and Delta variants respectively (Supplementary Table S2).
164 This suggests that the GMT for virus neutralization between 34 to 83 is required to
165 prevent infection from delta variant which is within the estimated values from
166 mathematical models[9]. As expected, participants with hybrid immunity were protected
167 from SARS-CoV-2 infection during the second wave and had very high levels of
168 neutralizing antibodies (Supplementary Table S3). While the neutralizing antibody levels
169 clearly showed a steep increase in participants who got infected during the second
170 wave (Figure 2 A-C), the same remained unchanged in those who were protected from
171 infection during the second wave (Figure 2D-E and Supplementary Table S2 and S3).
172 Exposure to delta variant led to generation of neutralizing antibodies for both Alpha
173 variant and SARS-CoV-2 B.6 lineage from the year 2020 (Figure 2A-C).

174
175 We were able to obtain a follow-up sample six months after two dose vaccination from
176 14 of our study participants. RBD-ELISA antibody titers reduced significantly ($P < 0.05$)

177 from a GMT of 237 (95% CI: 97, 584) to 76 (95% CI: 40, 146) within six months (Figure
178 2H). Similarly, the neutralizing antibody titers for delta variant in FRNT assays reduced
179 by two-fold from a GMT of 232 (95% CI: 100, 538) to 100 (66, 154) but this reduction
180 was not significant (Figure 2I). While this study was in progress Omicron (B.1.1.529)
181 emerged as a new variant of concern with over 30 substitutions in the Spike region
182 alone and multiple studies demonstrating neutralization escape [2, 10, 11]. We tested
183 these paired samples for neutralizing antibodies against Omicron. Only 5 out of 14
184 samples had detectable antibodies against Omicron. Only 2 out of 14 samples were
185 positive for Omicron in the follow up sample collected after six months (Figure 2J).
186 These data suggest that, while a subset of individuals who are both vaccinated and
187 exposed to natural infection may have antibodies against Omicron variant during early
188 convalescence, a large majority may either have insufficient or no antibodies against
189 this new VoC in the present situation in India which has led to a surge in infection.

190

191 **CONCLUSIONS**

192 This study was conducted during the second wave of COVID-19 in India when delta
193 variant was the major circulating strain. Our results are in concordance with previous
194 observations in people vaccinated with the mRNA vaccines (Pfizer-BioNTech) [12-14].
195 We see a convincing association between the pre-existing high antibody titers against
196 both Alpha and Delta variants and protection from re-infection in these individuals. Our
197 data suggests that a FRNT₅₀ of 34 - 83 may be sufficient to protect from delta variant
198 infection in younger adults. Interestingly, hybrid immunity led to generation of
199 neutralizing antibodies against the Alpha variant and the earlier B.6 lineage which

200 explains the reason for rapid decline in case load after July 2021 in India. However, the
201 same was not true for Omicron variant as only a subset of individuals had detectable
202 levels of antibodies to this VoC during early convalescence. Cohort data of patients with
203 mild COVID-19 infection has shown that RBD antibodies decay with a half-life of 69
204 days [15]. We observed a three-fold reduction in RBD antibody titers after six months,
205 however, neutralizing antibody levels reduced by 50% for delta variant and none of the
206 samples had any neutralizing antibodies to omicron after six months suggesting that
207 waning neutralizing titers are an important determinant of reinfections and may also
208 contribute to increased susceptibility to new VoCs that escape pre-existing humoral
209 immunity.

210

211 **Data availability**

212 All the data are presented in this manuscript. The following SARS-CoV-2 sequences
213 are available in NCBI database. SARS-CoV-2 to B.6 lineage (GenBank: MW422884.1)
214 [16]. Alpha variant or B.1.1.7 (GenBank: MW881790.1) and delta variant or B.1.617.2
215 (GenBank: MZ356566.1) and kappa variant or B.1.617.1 (GenBank: MZ356902.1).

216

217 **ACKNOWLEDGEMENTS**

218 We thank all the members of bioassay lab, COVID-19 testing team, Amresh Kumar
219 Singh and Maniram for technical support. We thank Jigme Wangchuk for help with
220 sequencing data analysis. We thank Neha Garg and Shamsheer Singh for data
221 management. We thank all the participants who consented to enrolment into the study.

222

223 **AUTHOR CONTRIBUTIONS**

224 JS, HS, BS, AA, KP, PC, PD, RM and PM performed experiments and analyzed the
225 data. NK and AKP coordinated the study at clinical site and contributed reagents. RP
226 designed the sequencing experiments and analyzed the data. GRM conceived the
227 study, designed the experiments, and analyzed the data. GRM wrote the manuscript. All
228 authors have reviewed and approved the final version of the manuscript.

229

230 **FUNDING INFORMATION**

231 This work was supported by the Department of Biotechnology (DBT) grants through
232 IndCEPI Mission (BT/MB/CEPI/2016) and Translational Research Program
233 (BT/PR30159/MED/15/188/2018). RP acknowledges funding support from IUSSTF
234 (CLP-0033) and BMGF (CLP-0036). The funders had no role in study design, data
235 collection and interpretation or the decision to submit the work for publication.

236

237 **CONFLICT OF INTEREST STATEMENT**

238 The authors have declared that no conflict of interest exists.

239

240 **REFERENCES**

241 [1] Anantharaj A, Gujjar S, Verma N, Khan NA, Shaman H, Sharanabasava P, et al.
242 Resolution of viral load in mild COVID-19 patients is associated with both innate and
243 adaptive immune responses. *Journal of Clinical Virology*. 2022;146:105060.
244 [2] Medigeshi G, Batra G, Murugesan DR, Thiruvengadam R, Chattopadhyay S, Das B,
245 et al. Sub-optimal Neutralisation of Omicron (B.1.1.529) Variant by Antibodies induced

246 by Vaccine alone or SARS-CoV-2 Infection plus Vaccine (Hybrid Immunity) post 6-
247 months. medRxiv. 2022:2022.01.04.22268747.

248 [3] Desai D, Khan AR, Soneja M, Mittal A, Naik S, Kodan P, et al. Effectiveness of an
249 inactivated virus-based SARS-CoV-2 vaccine, BBV152, in India: a test-negative, case-
250 control study. *Lancet Infect Dis*. 2021.

251 [4] Mlcochova P, Kemp S, Dhar MS, Papa G, Meng B, Ferreira I, et al. SARS-CoV-2
252 B.1.617.2 Delta variant replication and immune evasion. *Nature*. 2021.

253 [5] Planas D, Veyer D, Baidaliuk A, Staropoli I, Guivel-Benhassine F, Rajah MM, et al.
254 Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. *Nature*.
255 2021;596:276-80.

256 [6] Thiruvengadam R, Awasthi A, Medigeshi G, Bhattacharya S, Mani S, Sivasubbu S,
257 et al. Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during
258 the delta (B.1.617.2) variant surge in India: a test-negative, case-control study and a
259 mechanistic study of post-vaccination immune responses. *The Lancet Infectious*
260 *Diseases*. 2021.

261 [7] Yadav PD, Sapkal GN, Ella R, Sahay RR, Nyayanit DA, Patil DY, et al.
262 Neutralization against B.1.351 and B.1.617.2 with sera of COVID-19 recovered cases
263 and vaccinees of BBV152. *bioRxiv*. 2021:2021.06.05.447177.

264 [8] Dhar MS, Marwal R, Radhakrishnan V, Ponnusamy K, Jolly B, Bhojar RC, et al.
265 Genomic characterization and Epidemiology of an emerging SARS-CoV-2 variant in
266 Delhi, India. *medRxiv*. 2021:2021.06.02.21258076.

- 267 [9] Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al.
268 Neutralizing antibody levels are highly predictive of immune protection from
269 symptomatic SARS-CoV-2 infection. *Nat Med.* 2021;27:1205-11.
- 270 [10] Dejnirattisai W, Shaw RH, Supasa P, Liu C, Stuart AS, Pollard AJ, et al. Reduced
271 neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum.
272 *Lancet.* 2021.
- 273 [11] Meng B, Ferreira IATM, Abdullahi A, Saito A, Kimura I, Yamasoba D, et al. SARS-
274 CoV-2 Omicron spike mediated immune escape, infectivity and cell-cell fusion. *bioRxiv.*
275 2021:2021.12.17.473248.
- 276 [12] Ebinger JE, Fert-Bober J, Printsev I, Wu M, Sun N, Figueiredo JC, et al. Prior
277 COVID-19 Infection and Antibody Response to Single Versus Double Dose mRNA
278 SARS-CoV-2 Vaccination. *medRxiv.* 2021.
- 279 [13] Fraley E, LeMaster C, Geanes E, Banerjee D, Khanal S, Grundberg E, et al.
280 Humoral immune responses during SARS-CoV-2 mRNA vaccine administration in
281 seropositive and seronegative individuals. *BMC Med.* 2021;19:169.
- 282 [14] Krammer F, Srivastava K, Alshammary H, Amoako AA, Awawda MH, Beach KF, et
283 al. Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2
284 mRNA Vaccine. *N Engl J Med.* 2021;384:1372-4.
- 285 [15] Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, et al. Immunological
286 memory to SARS-CoV-2 assessed for up to 8 months after infection. *Science.*
287 2021;371.
- 288 [16] Anantharaj A, Gujjar S, Kumar S, Verma N, Wangchuk J, Khan NA, et al. Kinetics
289 of viral load, immunological mediators and characterization of a SARS-CoV-2 isolate in

290 mild COVID-19 patients during acute phase of infection. medRxiv.
291 2020:2020.11.05.20226621.

292 **SUPPLEMENTARY INFORMATION**

293 Detailed methods description is provided as supplementary information.

294

295 **FIGURE LEGENDS**

296 **Figure 1: Quantitation of RBD antibodies by ELISA.** Serum levels of antibodies
297 against SARS-CoV-2 RBD was estimated by quantitative ELISA in study participants
298 after one dose of ChAdOx1 nCoV-19 vaccine. (A) Participants were sub-grouped based
299 on prior history of infection as uninfected, infected. Four non-vaccinated individuals
300 served as controls. (B) Pre-infection RBD antibody titers in participants who got infected
301 with COVID-19 after few days of receiving first dose of vaccine. Dotted line indicates the
302 limit of quantitation (C) RBD antibody titers in samples collected before and after
303 infection in participants who were COVID-19-positive and (D) RBD antibody titers from
304 samples collected at the same time-point from participants who did not get infected with
305 COVID-19 during the second wave. Data was expressed as ELU/ml (international units)
306 as the secondary reference reagent was calibrated against the WHO international
307 reference standard. P values are indicated by - * $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$; ns -
308 not significant.

309

310 **Figure 2: Estimation of 50% virus neutralization antibody titers by FRNT assay.**

311 (A-C) FRNT₅₀ titers for the three indicated virus lineages in paired samples collected
312 prior to and after infection in samples collected from participants who were RT-PCR

313 positive during the second wave. (D-F) FRNT₅₀ titers of samples from participants who
314 were not positive for COVID-19 during the second wave. (H) RBD-ELISA titers in paired
315 samples collected six months post-vaccination. (I) FRNT₅₀ titers in paired samples for
316 delta variant and (J) Omicron variant. BAU: Binding Antibody Units. P values are
317 indicated by - * p<0.05; ** p<0.01; *** p < 0.001; ns - not significant.

318

319

320 **Table 1: Virus neutralization titers post single-dose vaccination with or without**
321 **prior history of SARS-CoV-2 infection.**

Lineage tested in FRNT assay	B.6		B.1.1.7		B.1.617.2	
	+	-	+	-	+	-
Prior SARS-CoV-2 infection	+	-	+	-	+	-
Geometric mean	1873	110.2	1056	53.82	783.7	50.47
Lower 95% CI	366.4	70.40	133.1	36.83	132.2	31.59
Upper 95% CI	9574	172.5	8382	78.64	4646	80.64
P value [#]	0.0097		0.0188		0.0094	

322 * N = 6 for prior infection (+) and N=12 for no prior infection (-)

323 # P value determined by Mann-Whitney test

324

Figure 1




Figure 2

